EUVIMEDEUVIMED entdecken
Crossref

Preoperative Molecular Testing of Papillary Thyroid Cancer Using Thyroid GuidePx®: An Early Economic Analysis

Megan Wiggins, Ikennah L Browne, Steven Craig, Rui Fu, Oliver F Bathe

Journal of Surgery Research and Practice · 23.11.2026 · 7 (3) · 1-18

DOI: 10.46889/jsrp.2026.7305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgery Research and Practice, online erschienen am 23.11.2026. Verfasst von Megan Wiggins und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preoperative risk stratification in Papillary Thyroid Cancer (PTC) remains limited because current American Thyroid Association (ATA) criteria rely on postoperative pathology and explain only a small proportion of recurrence risk. Thyroid GuidePx®, an RNA-based prognostic classifier derived from machine-learning analysis of recurrence-associated transcripts, enables preoperative molecular risk stratification using fine-needle aspiration specimens. This study provides an early economic evaluation of Thyroid GuidePx® compared with Standard Care (SoC) from a U.S. payer perspective.

Methods

We built a hybrid decision tree and Markov model to simulate lifetime costs and outcomes for patients with PTC eligible for lobectomy under ATA guidelines. Model inputs were derived from published literature and validation data for Thyroid GuidePx®. The base-case analysis assumed no effect on long-term recurrence risk and set the test price to $0 to estimate the maximum economically justifiable price. Deterministic and probabilistic sensitivity analyses explored parameter uncertainty. Costs (2024 USD) and utilities were discounted at 3% annually.

Results

Thyroid GuidePx® reclassified 17.95% of patients from high to low risk, enabling more index lobectomies and fewer completion thyroidectomies. Thyroid GuidePx® yielded an average gain of 0.18 QALYs and lifetime cost savings of $3,614 per patient relative to SoC. The maximum economically justifiable price was $12,832 (95% CI: $9,663-$16,515) and Thyroid GuidePx® remained cost-effective across wide ranges of surgical practice patterns.

Conclusion

This early evaluation suggests that Thyroid GuidePx® may improve quality-adjusted survival and reduce costs by enabling accurate preoperative risk stratification. Further real-world data will refine these estimates.

Zitieren

APA

Wiggins, M., Browne, I. L., Craig, S., Fu, R., & Bathe, O. F. (2026). Preoperative Molecular Testing of Papillary Thyroid Cancer Using Thyroid GuidePx®: An Early Economic Analysis. Journal of Surgery Research and Practice, 7(3), 1-18. https://doi.org/10.46889/jsrp.2026.7305

Vancouver

Wiggins M, Browne IL, Craig S, Fu R, Bathe OF. Preoperative Molecular Testing of Papillary Thyroid Cancer Using Thyroid GuidePx®: An Early Economic Analysis. Journal of Surgery Research and Practice. 2026;7(3):1-18. doi:10.46889/jsrp.2026.7305

BibTeX
@article{Wiggins2026,
  author = {Wiggins, Megan and Browne, Ikennah L and Craig, Steven and Fu, Rui and Bathe, Oliver F},
  title = {Preoperative Molecular Testing of Papillary Thyroid Cancer Using Thyroid GuidePx®: An Early Economic Analysis},
  journal = {Journal of Surgery Research and Practice},
  year = {2026},
  volume = {7},
  number = {3},
  pages = {1--18},
  doi = {10.46889/jsrp.2026.7305}
}
Kostenlos starten →